{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:08:23Z","timestamp":1778458103758,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2221-E-006-196"],"award-info":[{"award-number":["112-2221-E-006-196"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2628-E-110-007-MY3"],"award-info":[{"award-number":["111-2628-E-110-007-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04347-9","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:25:10Z","timestamp":1774887910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["pH-responsive virus-drug conjugates for targeted PD-L1 silencing and enhanced cancer immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1299-7202","authenticated-orcid":false,"given":"S.-Ja","family":"Tseng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan M.","family":"Kempson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Cheng","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan-Chyr","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-0728","authenticated-orcid":false,"given":"Zi-Xian","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"8062","key":"4347_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","volume":"641","author":"Y Shen","year":"2025","unstructured":"Shen Y, Bai X, Zhang Q, Liang X, Jin X, Zhao Z, Song W, Tan Q, Zhao R, Jia W, et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature. 2025;641(8062):503\u201311.","journal-title":"Nature"},{"issue":"1","key":"4347_CR2","doi-asserted-by":"publisher","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","volume":"5","author":"J Pol","year":"2016","unstructured":"Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5(1):e1115641.","journal-title":"Oncoimmunology"},{"key":"4347_CR3","doi-asserted-by":"publisher","first-page":"108521","DOI":"10.1016\/j.pharmthera.2023.108521","volume":"250","author":"ZX Liao","year":"2023","unstructured":"Liao ZX, Hsu S-h, Tang SC, Kempson I, Yang PC, Tseng SJ. Potential targeting of the tumor microenvironment to improve cancer virotherapy. Pharmacol Ther. 2023;250:108521.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"4347_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","volume":"23","author":"K Liu","year":"2024","unstructured":"Liu K, Li M, Li Y, Li Y, Chen Z, Tang Y, Yang M, Deng G, Liu H. A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers. Mol Cancer. 2024;23(1):62.","journal-title":"Mol Cancer"},{"issue":"11","key":"4347_CR5","doi-asserted-by":"publisher","first-page":"104165","DOI":"10.1016\/j.drudis.2024.104165","volume":"29","author":"ZX Liao","year":"2024","unstructured":"Liao ZX, Huang PH, Hsu S-h, Chang HH, Chang CH, Tseng SJ. Clinical strategies with antibody\u2013drug conjugates as potential modifications for virotherapy. Drug Discov Today. 2024;29(11):104165.","journal-title":"Drug Discov Today"},{"issue":"6","key":"4347_CR6","doi-asserted-by":"publisher","first-page":"102685","DOI":"10.1016\/j.isci.2021.102685","volume":"24","author":"H Gong","year":"2021","unstructured":"Gong H, Yuan N, Shen Z, Tang C, Shipp S, Qian L, Lu Y, Andolina IM, Zhang S, Wu J, et al. Transduction catalysis: Doxorubicin amplifies rAAV-mediated gene expression in the cortex of higher-order vertebrates. iScience. 2021;24(6):102685.","journal-title":"iScience"},{"issue":"1","key":"4347_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23(1):108.","journal-title":"Mol Cancer"},{"issue":"11","key":"4347_CR8","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42(11):1825\u201363.","journal-title":"Cancer Cell"},{"issue":"1","key":"4347_CR9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","volume":"21","author":"SS Ali Zaidi","year":"2023","unstructured":"Ali Zaidi SS, Fatima F, Ali Zaidi SA, Zhou D, Deng W, Liu S. Engineering siRNA therapeutics: challenges and strategies. J Nanobiotechnol. 2023;21(1):381.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4347_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12951-023-01960-w","volume":"21","author":"Z Wang","year":"2023","unstructured":"Wang Z, Tang XL, Zhao MJ, Zhang YD, Xiao Y, Liu YY, Qian CF, Xie YD, Liu Y, Zou YJ, et al. Biomimetic hypoxia-triggered RNAi nanomedicine for synergistically mediating chemo\/radiotherapy of glioblastoma. J Nanobiotechnol. 2023;21(1):210.","journal-title":"J Nanobiotechnol"},{"issue":"9","key":"4347_CR11","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1073\/pnas.092143499","volume":"99","author":"JY Yu","year":"2002","unstructured":"Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA. 2002;99(9):6047\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"4347_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","volume":"30","author":"NL Meyer","year":"2022","unstructured":"Meyer NL, Chapman MS. Adeno-associated virus (AAV) cell entry: structural insights. Trends Microbiol. 2022;30(5):432\u201351.","journal-title":"Trends Microbiol"},{"issue":"3","key":"4347_CR13","doi-asserted-by":"publisher","first-page":"113902","DOI":"10.1016\/j.celrep.2024.113902","volume":"43","author":"EJ Loeb","year":"2024","unstructured":"Loeb EJ, Havlik PL, Elmore ZC, Rosales A, Fergione SM, Gonzalez TJ, Smith TJ, Benkert AR, Fiflis DN, Asokan A. Capsid-mediated control of adeno-associated viral transcription determines host range. Cell Rep. 2024;43(3):113902.","journal-title":"Cell Rep"},{"issue":"4","key":"4347_CR14","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/hep4.1842","volume":"6","author":"C Zhang","year":"2022","unstructured":"Zhang C, Freistaedter A, Schmelas C, Gunkel M, Dao Thi VL, Grimm D. An RNA Interference\/Adeno-Associated Virus Vector-Based Combinatorial Gene Therapy Approach Against Hepatitis E Virus. Hepatol Commun. 2022;6(4):878\u201388.","journal-title":"Hepatol Commun"},{"issue":"1","key":"4347_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9(1):78.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"4347_CR16","doi-asserted-by":"publisher","first-page":"9894","DOI":"10.1021\/acsnano.8b02813","volume":"12","author":"SJ Tseng","year":"2018","unstructured":"Tseng SJ, Kempson IM, Huang KY, Li HJ, Fa YC, Ho YC, Liao ZX, Yang PC. Targeting Tumor Microenvironment by Bioreduction-Activated Nanoparticles for Light-Triggered Virotherapy. ACS Nano. 2018;12(10):9894\u2013902.","journal-title":"ACS Nano"},{"key":"4347_CR17","doi-asserted-by":"publisher","first-page":"101582","DOI":"10.1016\/j.nantod.2022.101582","volume":"46","author":"SJ Tseng","year":"2022","unstructured":"Tseng SJ, Kempson IM, Liao ZX, Ho YC, Yang PC. An acid degradable, lactate oxidizing nanoparticle formulation for non-small cell lung cancer virotherapy. Nano Today. 2022;46:101582.","journal-title":"Nano Today"},{"key":"4347_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/IJN.S504629","volume":"20","author":"Y Liu","year":"2025","unstructured":"Liu Y, Si L, Jiang Y, Jiang S, Zhang X, Li S, Chen J, Hu J. Design of pH-Responsive Nanomaterials Based on the Tumor Microenvironment. Int J Nanomed. 2025;20:705\u201321.","journal-title":"Int J Nanomed"},{"issue":"7","key":"4347_CR19","doi-asserted-by":"publisher","first-page":"e1010187","DOI":"10.1371\/journal.ppat.1010187","volume":"18","author":"SO Sutter","year":"2022","unstructured":"Sutter SO, Lkharrazi A, Schraner EM, Michaelsen K, Meier AF, Marx J, Vogt B, B\u00fcning H, Fraefel C. Adeno-associated virus type 2 (AAV2) uncoating is a stepwise process and is linked to structural reorganization of the nucleolus. PLoS Pathog. 2022;18(7):e1010187.","journal-title":"PLoS Pathog"},{"issue":"7","key":"4347_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440\u20136.","journal-title":"Pharmacogenet Genomics"},{"issue":"22","key":"4347_CR21","doi-asserted-by":"publisher","first-page":"11040","DOI":"10.1128\/JVI.01056-06","volume":"80","author":"F Sonntag","year":"2006","unstructured":"Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt J\u00fcrgen A. Adeno-Associated Virus Type 2 Capsids with Externalized VP1\/VP2 Trafficking Domains Are Generated prior to Passage through the Cytoplasm and Are Maintained until Uncoating Occurs in the Nucleus. J Virol. 2006;80(22):11040\u201354.","journal-title":"J Virol"},{"issue":"5","key":"4347_CR22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ccell.2023.04.003","volume":"41","author":"A Obradovic","year":"2023","unstructured":"Obradovic A, Ager C, Turunen M, Nirschl T, Khosravi-Maharlooei M, Iuga A, Jackson CM, Yegnasubramanian S, Tomassoni L, Fernandez EC, et al. Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators. Cancer Cell. 2023;41(5):933\u2013e4911.","journal-title":"Cancer Cell"},{"issue":"1","key":"4347_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-023-00989-1","volume":"31","author":"DL Ou","year":"2024","unstructured":"Ou DL, Liao ZX, Kempson IM, Li L, Yang PC, Tseng SJ. Nano-modified viruses prime the tumor microenvironment and promote the photodynamic virotherapy in liver cancer. J Biomed Sci. 2024;31(1):1.","journal-title":"J Biomed Sci"},{"issue":"6","key":"4347_CR24","doi-asserted-by":"publisher","first-page":"2100048","DOI":"10.1002\/adtp.202100048","volume":"4","author":"DL Ou","year":"2021","unstructured":"Ou DL, Tseng SJ, Kempson IM, Hsu CL, Yang PC, Liao ZX. Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer. Adv Ther. 2021;4(6):2100048.","journal-title":"Adv Ther"},{"issue":"6","key":"4347_CR25","doi-asserted-by":"publisher","first-page":"14872","DOI":"10.1080\/21655979.2022.2162660","volume":"13","author":"M Qin","year":"2022","unstructured":"Qin M, Chen G, Hou J, Wang L, Wang Q, Wang L, Jiang D, Hu Y, Xie B, Chen J, et al. Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer. Bioengineered. 2022;13(6):14872\u201388.","journal-title":"Bioengineered"},{"issue":"1","key":"4347_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res. 2025;44(1):145.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"4347_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.cgt.7700282","volume":"8","author":"T Kanazawa","year":"2001","unstructured":"Kanazawa T, Urabe M, Mizukami H, Okada T, Kume A, Nishino H, Monahan J, Kitamura K, Ichimura K, Ozawa K. Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk\/ganciclovir on cancer cells. Cancer Gene Ther. 2001;8(2):99\u2013106.","journal-title":"Cancer Gene Ther"},{"issue":"16","key":"4347_CR28","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.1128\/JVI.02953-15","volume":"90","author":"SC Nicolson","year":"2016","unstructured":"Nicolson SC, Li C, Hirsch ML, Setola V, Samulski RJ. Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens. J Virol. 2016;90(16):7019\u201331.","journal-title":"J Virol"},{"issue":"6","key":"4347_CR29","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1128\/JVI.78.6.2863-2874.2004","volume":"78","author":"Z Yan","year":"2004","unstructured":"Yan Z, Zak R, Zhang Y, Ding W, Godwin S, Munson K, Peluso R, Engelhardt JF. Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol. 2004;78(6):2863\u201374.","journal-title":"J Virol"},{"key":"4347_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jconrel.2023.09.003","volume":"363","author":"G Miao","year":"2023","unstructured":"Miao G, He Y, Lai K, Zhao Y, He P, Tan G, Wang X. Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients. J Control Release. 2023;363:12\u201326.","journal-title":"J Control Release"},{"key":"4347_CR31","doi-asserted-by":"publisher","first-page":"125931","DOI":"10.1016\/j.ijpharm.2025.125931","volume":"682","author":"S Tapponi","year":"2025","unstructured":"Tapponi S, Yusuf A, Alsaafin F, Hussain Z. Breaking barriers with pH-responsive nanocarriers: a new frontier in precision oncology. Int J Pharm. 2025;682:125931.","journal-title":"Int J Pharm"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04347-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04347-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04347-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T23:13:13Z","timestamp":1778454793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04347-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4347"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04347-9","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"425"}}